122 related articles for article (PubMed ID: 28052599)
21. Variations in supportive care needs of patients after diagnosis of localised cutaneous melanoma: a 2-year follow-up study.
Beesley VL; Smithers BM; O'Rourke P; Janda M; Khosrotehrani K; Green AC
Support Care Cancer; 2017 Jan; 25(1):93-102. PubMed ID: 27562298
[TBL] [Abstract][Full Text] [Related]
22. Quality of life in localised malignant melanoma.
Schlesinger-Raab A; Schubert-Fritschle G; Hein R; Stolz W; Volkenandt M; Hölzel D; Engel J
Ann Oncol; 2010 Dec; 21(12):2428-2435. PubMed ID: 20494965
[TBL] [Abstract][Full Text] [Related]
23. Spotlight on the Fear of Cancer Recurrence Inventory (FCRI).
Smith AB; Costa D; Galica J; Lebel S; Tauber N; van Helmondt SJ; Zachariae R
Psychol Res Behav Manag; 2020; 13():1257-1268. PubMed ID: 33376421
[TBL] [Abstract][Full Text] [Related]
24. Psychometric properties of the Japanese version of the Concerns About Recurrence Scale (CARS-J).
Momino K; Akechi T; Yamashita T; Fujita T; Hayahi H; Tsunoda N; Miyashita M; Iwata H
Jpn J Clin Oncol; 2014 May; 44(5):456-62. PubMed ID: 24711631
[TBL] [Abstract][Full Text] [Related]
25. The health-related quality of life of long-term survivors of melanoma treated with isolated limb perfusion.
Noorda EM; van Kreij RH; Vrouenraets BC; Nieweg OE; Muller M; Kroon BB; Aaronson NK
Eur J Surg Oncol; 2007 Aug; 33(6):776-82. PubMed ID: 17300914
[TBL] [Abstract][Full Text] [Related]
26. Illness-related distress in women with clinically localized cutaneous melanoma.
Atkinson TM; Noce NS; Hay J; Rafferty BT; Brady MS
Ann Surg Oncol; 2013 Feb; 20(2):675-9. PubMed ID: 22965568
[TBL] [Abstract][Full Text] [Related]
27. Psychological factors in the prognosis of malignant melanoma: a prospective study.
Rogentine GN; van Kammen DP; Fox BH; Docherty JP; Rosenblatt JE; Boyd SC; Bunney WE
Psychosom Med; 1979 Dec; 41(8):647-55. PubMed ID: 545425
[TBL] [Abstract][Full Text] [Related]
28. Factor structure of the Fear of Cancer Recurrence Inventory (FCRI): Comparison of international FCRI factor structure data and factor analysis of the Dutch FCRI-NL using three predominantly breast cancer samples.
van Helmondt SJ; van der Lee ML; Bisseling EM; Lodder P; de Vries J
Eur J Cancer Care (Engl); 2021 Sep; 30(5):e13431. PubMed ID: 33763943
[TBL] [Abstract][Full Text] [Related]
29. Anxiety and depressive symptoms measured by the Hospital Anxiety and Depression Scale as predictors of time to recurrence in localized cutaneous melanoma.
Bergenmar M; Nilsson B; Hansson J; Brandberg Y
Acta Oncol; 2004; 43(2):161-8. PubMed ID: 15163164
[TBL] [Abstract][Full Text] [Related]
30. Recurrence of cutaneous malignant melanoma after more than 20 years.
Bredgaard R; Lock-Andersen J
J Plast Surg Hand Surg; 2011 Apr; 45(2):113-6. PubMed ID: 21504283
[TBL] [Abstract][Full Text] [Related]
31. Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma.
Turner RM; Bell KJ; Morton RL; Hayen A; Francken AB; Howard K; Armstrong B; Thompson JF; Irwig L
J Clin Oncol; 2011 Dec; 29(35):4641-6. PubMed ID: 22067399
[TBL] [Abstract][Full Text] [Related]
32. The Cancer Worry Scale: detecting fear of recurrence in breast cancer survivors.
Custers JA; van den Berg SW; van Laarhoven HW; Bleiker EM; Gielissen MF; Prins JB
Cancer Nurs; 2014; 37(1):E44-50. PubMed ID: 23448956
[TBL] [Abstract][Full Text] [Related]
33. Internet use and anxiety in people with melanoma and nonmelanoma skin cancer.
Ludgate MW; Sabel MS; Fullen DR; Frohm ML; Lee JS; Couper MP; Johnson TM; Bichakjian CK
Dermatol Surg; 2011 Sep; 37(9):1252-9. PubMed ID: 22988988
[TBL] [Abstract][Full Text] [Related]
34. Pediatric melanoma: an opportunity for psychosocial research.
Schwartz JL; Mollen E; Ludgate MW; Riba MB; Johnson TM
J Am Acad Dermatol; 2010 May; 62(5):892-3. PubMed ID: 20398821
[No Abstract] [Full Text] [Related]
35. The role of psychological variables in a group of melanoma patients. An Israeli sample.
Baider L; Perry S; Sison A; Holland J; Uziely B; DeNour AK
Psychosomatics; 1997; 38(1):45-53. PubMed ID: 8997116
[TBL] [Abstract][Full Text] [Related]
36. Surgical management of primary and recurrent melanoma.
Farma JM; Kulkarni N; Hsu C
Surg Oncol Clin N Am; 2015 Apr; 24(2):239-47. PubMed ID: 25769709
[TBL] [Abstract][Full Text] [Related]
37. The MELFO-Study: Prospective, Randomized, Clinical Trial for the Evaluation of a Stage-adjusted Reduced Follow-up Schedule in Cutaneous Melanoma Patients-Results after 1 Year.
Damude S; Hoekstra-Weebers JE; Francken AB; Ter Meulen S; Bastiaannet E; Hoekstra HJ
Ann Surg Oncol; 2016 Sep; 23(9):2762-71. PubMed ID: 27194552
[TBL] [Abstract][Full Text] [Related]
38. Fear of cancer recurrence in colorectal cancer survivors.
Custers JAE; Gielissen MFM; Janssen SHV; de Wilt JHW; Prins JB
Support Care Cancer; 2016 Feb; 24(2):555-562. PubMed ID: 26108170
[TBL] [Abstract][Full Text] [Related]
39. The Melanoma care study: protocol of a randomised controlled trial of a psycho-educational intervention for melanoma survivors at high risk of developing new primary disease.
Dieng M; Kasparian NA; Morton RL; Mann GJ; Butow P; Menzies S; Costa DS; Cust AE
BMC Psychol; 2015; 3(1):23. PubMed ID: 26167282
[TBL] [Abstract][Full Text] [Related]
40. Frequency of residual melanoma in wide local excision (WLE) specimens after complete excisional biopsy.
Bolshinsky V; Lin MJ; Serpell J; Leung M; Wolfe R; McLean C; Kelly JW
J Am Acad Dermatol; 2016 Jan; 74(1):102-7. PubMed ID: 26601566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
